Compounded GLP-1s are not FDA-approved products. FDA review covers the approved drug's molecule and the manufacturer's production process; it does not cover each compounded batch. That does not make every compounded product dangerous, but it moves quality assurance onto the individual pharmacy, and the specific concerns are documented ones: sterility, potency accuracy, dosing errors, unapproved salt forms and outright counterfeits.
Compounded, approved and counterfeit are three different categories
A compounded GLP-1 is neither demonstrably equivalent to the branded drug nor uniformly unsafe. What separates one product from another is the regulatory category it falls into, the type of pharmacy that prepared it, and the active ingredient it actually contains. Those three facts are knowable for any specific product, and they determine almost everything about its risk. → GLP-1 hub
FDA-approved versus compounded
FDA-approved semaglutide (Wegovy/Ozempic/Rybelsus) and tirzepatide (Zepbound/Mounjaro) pass through review of the molecule's safety and efficacy and of the manufacturer's production, sterility, potency and consistency. Every batch is made to that standard.
Compounded drugs are prepared by a pharmacy for an individual need. Compounding is a legitimate, long-standing part of medicine, but a compounded drug is not FDA-approved, is not reviewed batch by batch, and its quality depends on the pharmacy that makes it. The FDA does not verify that a given compounded vial contains what its label says. The distinction is not fake versus real; it is individually assured by a pharmacy versus reviewed and standardised by the FDA. Grade A 🟢 (regulatory fact).
The shortage context and why it has shifted
Large-scale compounding of GLP-1s expanded because the branded drugs were placed on the FDA drug-shortage list. Under specific rules, compounders may prepare a drug that is otherwise commercially available while it is in shortage, which opened a legal window and a large market.
When a drug comes off the shortage list, the legal basis for compounding it narrows or closes, and that has now happened. The FDA declared the shortages resolved (tirzepatide in December 2024, semaglutide in February 2025), and the enforcement grace periods ended in mid-2025. Routine mass-compounding of what are essentially copies of these drugs is therefore no longer permitted; 503A and 503B pharmacies may compound them only in narrow, patient-specific circumstances, such as a documented clinical need the approved product cannot meet. Compounded versions remain non-FDA-approved, and the legal standing of some telehealth "personalised-dose" arrangements is contested. This status is time-sensitive and should be re-checked at the point of care. Grade B 🟡
503A versus 503B — who made it
Two different kinds of pharmacy operate under different rules:
- 503A compounding pharmacies — traditional pharmacies compounding against an individual patient prescription. Overseen mainly by state boards of pharmacy, not routinely FDA-inspected for manufacturing.
- 503B outsourcing facilities — registered with the FDA, subject to federal Good Manufacturing Practice (cGMP) standards and FDA inspection, and able to make larger batches. A higher and more consistent quality bar than 503A.
Neither produces an FDA-approved product, but a 503B outsourcing facility works under stricter, federally inspected controls than a typical 503A pharmacy, and far stricter than an unregulated online seller. Which category made a given product is among the most informative facts available about it. Grade B 🟡
Quality and sterility
GLP-1s are injectable, so sterility is a requirement rather than a preference. The documented quality problems in compounded and grey-market products are these:
- Contamination or non-sterility — a hazard for any injectable made outside rigorous controls.
- Sub- or super-potency — a vial containing less or more active drug than labelled, from imprecise formulation.
- Impurities and degradation — from poor-quality active ingredient, or improper storage and reconstitution.
- Inadequate stability data — how long the product stays potent and sterile after mixing may be unknown.
These are the predictable failure modes when batch-level FDA review is absent and the pharmacy's own standards are the only safeguard. Grade B 🟡
Dosing errors
The best-documented harm from compounded GLP-1s is dosing error rather than any exotic toxicity. Compounded products come in different concentrations from the branded pens, so a "unit" or a "click" in one product does not equal another. Doses are often drawn from multi-dose vials with syringes, which invites ten-fold errors when units, milligrams and millilitres are confused. Instructions vary by pharmacy, and the error-resistant pen devices used by the branded products are frequently absent.
Overdoses from these errors have caused severe nausea, vomiting, dehydration and hospital visits. The problem lies in product design and instructions as much as in chemistry. Grade B 🟡
EVIDENCE CARD · Compounded GLP-1 safety
- WHAT'S SHOWN: Compounded GLP-1s are not FDA-approved or batch-reviewed; documented harms include dosing errors, and quality and sterility vary by pharmacy. Regulators have warned about unapproved salt forms and counterfeits.
- WHAT'S UNKNOWN: The true rate of harm across the many products and pharmacies; the potency, sterility and stability of any specific unverified vial.
- OUR POSITION: Not uniformly dangerous, but quality assurance shifts to the pharmacy, and the source matters: a 503B facility is a different proposition from an unverified online seller. In our practice, FDA-approved products are preferred, and a compounded product is used only where the pharmacy and ingredient can be verified. Grade B 🟡
Salt forms — semaglutide sodium and semaglutide acetate
The approved products contain semaglutide as the studied base molecule. Some compounded and grey-market products have instead used salt forms: semaglutide sodium or semaglutide acetate.
- These salt forms are not the same as the FDA-approved active ingredient, and the FDA has stated they are not shown to be safe and effective and generally should not be used in compounding.
- Salt forms have at times been sold as if equivalent, or labelled as "research use only" peptides, which places them outside the oversight that applies to medicines.
- Their efficacy and safety have not been established in the way the approved base molecule's have.
A product labelled "semaglutide sodium", "semaglutide acetate" or "research / not for human use" is therefore not the studied drug. Grade C 🟠 (safety and efficacy of salt forms not established).
Counterfeits and the grey market
Separate from legitimate compounding sits the highest-risk category: counterfeit and grey-market products — fake branded pens, "peptides" sold online, and vials of unknown origin. These may contain the wrong amount of drug, the wrong substance, or contaminants, and regulators have seized counterfeit GLP-1 pens. An unverified website or a "research chemical" shipment supports no claim about what the vial holds. Grade B 🟡
Where compounding has a legitimate role
Compounding is not inherently illegitimate. Reasonable situations include a documented allergy or intolerance to an inactive ingredient in the approved product, a specific formulation need, or a genuine, current shortage of the approved drug under the applicable rules. These are clinically justified, pharmacist-supervised uses. Where compounding is used, a 503B outsourcing facility and a pharmacy whose licensure and testing can be verified are the safer route. Grade C 🟠
What distinguishes a safer compounded product
Six facts separate a verifiable compounded product from an unverifiable one: whether it is FDA-approved or compounded; whether the preparer is a licensed 503A pharmacy or a 503B outsourcing facility; whether the active ingredient is semaglutide or tirzepatide base rather than a salt form or a "research" peptide; the concentration and how the dose is measured, by pen or by vial and syringe; what sterility, potency and stability testing each batch receives, and whether a certificate of analysis exists; and the storage conditions and beyond-use date after mixing. A pharmacy able to document all six is in a different position from one that cannot. Grade B 🟡
Questions patients ask
Is compounded semaglutide safe?
It is not FDA-approved or batch-reviewed, so safety depends heavily on the pharmacy. A reputable 503B facility differs greatly from a grey-market seller; documented harms include dosing errors and quality problems. Grade B 🟡
Is compounded the same drug as Wegovy or Ozempic?
Not necessarily — it may use the same base molecule or an unapproved salt form, and it is not made to the FDA-reviewed standard of the branded product. Grade B 🟡
Why is compounding even allowed?
Compounding is a legitimate practice, and shortage rules opened a window for GLP-1s specifically. That window has largely closed: the FDA declared the shortages resolved (tirzepatide Dec 2024, semaglutide Feb 2025) and grace periods ended in mid-2025, so routine mass-compounding of essentially-copy products is no longer permitted — only narrow, patient-specific compounding remains. Grade B 🟡
What is a salt form and why does it matter?
Semaglutide sodium and semaglutide acetate are not the approved active ingredient, and the FDA states they are not shown to be safe and effective. Grade C 🟠
Are "research peptides" a cheaper route to the same drug?
No — products labelled "research / not for human use" fall outside medicines oversight, may be salt forms or counterfeits, and are among the riskiest options. Grade B 🟡
How do dosing errors happen?
Different concentrations and vial-and-syringe dosing invite ten-fold mistakes, unlike the error-resistant branded pens. Grade B 🟡
Whether a compounded product has any place in a particular treatment plan, and which approved option fits instead, is assessed individually at the practice.
Written by Darius A. Schneider, MD, PhD · Board-Certified Endocrinologist (ECNU) · Last updated: Oct 2026 · References: FDA guidance and statements on compounded semaglutide/tirzepatide, salt forms and drug-shortage compounding; 503A/503B statutory framework; regulatory alerts on counterfeit GLP-1 products. Regulatory and shortage status is time-sensitive — verify at point of care. Educational; not individualized medical advice.
